Ozmosi | Trientine Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Trientine

Alternative Names: trientine, syprine
Clinical Status: Active
Latest Update: 2025-09-29
Latest Update Note: Clinical Trial Update

Product Description

Trientine is an oral copper chelating agent used to treat Wilson disease. Trientine has not been associated with worsening of serum enzyme elevations during therapy or with cases of clinically apparent liver injury with jaundice. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31643449/)

Mechanisms of Action: Copper Binder

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Austria | Canada | Croatia | Czech | Denmark | Estonia | Finland | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | Sweden | Switzerland

Approved Indications: None

Known Adverse Events: None

Company: Univar
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Trientine

Countries in Clinic: China, United Kingdom, United States

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Cardiomyopathy, Hypertrophic|Heart Failure, Chronic|Heart Failure, Systolic

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT04706429

TEMPEST

P2

Completed

Cardiomyopathy, Hypertrophic

2024-04-30

75%

2025-09-30

Primary Endpoints|Study Completion Date|Treatments|Trial Status

CTR20211406

CTR20211406

P2

Active, not recruiting

Heart Failure, Chronic|Heart Failure, Systolic

None

2025-04-29

Patient Enrollment|Start Date